Research analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.
Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.
Get Our Latest Stock Analysis on VolitionRx
VolitionRx Price Performance
VolitionRx (NYSE:VNRX – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. On average, analysts expect that VolitionRx will post -0.31 EPS for the current year.
Institutional Trading of VolitionRx
An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Articles
- Five stocks we like better than VolitionRx
- 3 Warren Buffett Stocks to Buy Now
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Stock Dividend Cuts Happen Are You Ready?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Want to Profit on the Downtrend? Downtrends, Explained.
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.